ATE466595T1 - Verbindungen und methoden für das downregulating der effekte von tgf-beta - Google Patents
Verbindungen und methoden für das downregulating der effekte von tgf-betaInfo
- Publication number
- ATE466595T1 ATE466595T1 AT04737968T AT04737968T ATE466595T1 AT E466595 T1 ATE466595 T1 AT E466595T1 AT 04737968 T AT04737968 T AT 04737968T AT 04737968 T AT04737968 T AT 04737968T AT E466595 T1 ATE466595 T1 AT E466595T1
- Authority
- AT
- Austria
- Prior art keywords
- tgf
- beta
- methods
- downregulating
- compounds
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002222 downregulating effect Effects 0.000 title 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000004698 lymphocyte Anatomy 0.000 abstract 2
- 229940123329 Cathepsin B inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- -1 cancers Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48765903P | 2003-07-16 | 2003-07-16 | |
| PCT/CA2004/001036 WO2005007199A1 (en) | 2003-07-16 | 2004-07-15 | COMPOUNDS AND METHODS FOR DOWNREGULATING THE EFFECTS OF TGF-β |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466595T1 true ATE466595T1 (de) | 2010-05-15 |
Family
ID=34079387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04737968T ATE466595T1 (de) | 2003-07-16 | 2004-07-15 | Verbindungen und methoden für das downregulating der effekte von tgf-beta |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050036994A1 (de) |
| EP (1) | EP1648520B1 (de) |
| JP (1) | JP2007528862A (de) |
| CN (1) | CN1852741A (de) |
| AT (1) | ATE466595T1 (de) |
| AU (1) | AU2004257367A1 (de) |
| CA (1) | CA2532630A1 (de) |
| DE (1) | DE602004027048D1 (de) |
| HK (1) | HK1091127A1 (de) |
| WO (1) | WO2005007199A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| US8729133B2 (en) * | 2006-02-28 | 2014-05-20 | Cornell University | Method for treating cancer |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
| EP2560953B1 (de) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Hemmer der glutaminylzyklase |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| WO2013148155A1 (en) * | 2012-03-26 | 2013-10-03 | Digna Biotech Usa, Llc | Compositions and methods for the treatment of dry eye disease |
| ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
| WO2018195339A1 (en) * | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| KR20230024249A (ko) * | 2020-03-11 | 2023-02-20 | 우니베르지테트 베른 | 신장 장애의 치료를 위한 페투인 a |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543143A (en) * | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
| US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| EP0695354B1 (de) * | 1993-04-30 | 2002-01-09 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
| ATE235549T1 (de) * | 1993-04-30 | 2003-04-15 | Biognostik Ges | Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2 |
| DE69523750T2 (de) * | 1994-05-04 | 2002-08-01 | Mount Sinai Hospital Corp | Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung |
| US5827702A (en) * | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| US5622856A (en) * | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
| US6001650A (en) * | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6027931A (en) * | 1995-08-03 | 2000-02-22 | Avigen, Inc. | High-efficiency AA V helper functions |
| US6004797A (en) * | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| US5945335A (en) * | 1995-11-09 | 1999-08-31 | Avigen, Inc. | Adenovirus helper-free system for producing recombinant AAV virions lacking oncogenic sequences |
| AU5593398A (en) * | 1996-12-05 | 1998-06-29 | Alcon Laboratories, Inc. | The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology |
| US6200799B1 (en) * | 1997-06-03 | 2001-03-13 | University Of Lausanne | Somatic gene therapy to suppress secondary cataract formation following eye surgery |
| US6258779B1 (en) * | 1997-12-18 | 2001-07-10 | David Tsai | Method of using fetuin to induce apoptosis in cancer cells |
| US6489305B1 (en) * | 1998-05-08 | 2002-12-03 | Canji, Inc. | Methods and compositions for the treatment of ocular diseases |
| CA2330939A1 (en) * | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US6051401A (en) * | 1998-07-28 | 2000-04-18 | Bayer Corporation | Methods and constructs for protein expression |
| US6468524B1 (en) * | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US6855314B1 (en) * | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US20040198648A1 (en) * | 2000-10-27 | 2004-10-07 | George Grunberger | Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis |
| US20030044400A1 (en) * | 2001-05-22 | 2003-03-06 | Jenny Yu | Composition and method for treating cells |
-
2004
- 2004-07-15 CN CNA2004800266940A patent/CN1852741A/zh active Pending
- 2004-07-15 EP EP04737968A patent/EP1648520B1/de active Active
- 2004-07-15 WO PCT/CA2004/001036 patent/WO2005007199A1/en active Application Filing
- 2004-07-15 DE DE602004027048T patent/DE602004027048D1/de not_active Expired - Fee Related
- 2004-07-15 CA CA002532630A patent/CA2532630A1/en not_active Abandoned
- 2004-07-15 AU AU2004257367A patent/AU2004257367A1/en not_active Abandoned
- 2004-07-15 US US10/891,943 patent/US20050036994A1/en not_active Abandoned
- 2004-07-15 JP JP2006519736A patent/JP2007528862A/ja not_active Withdrawn
- 2004-07-15 AT AT04737968T patent/ATE466595T1/de not_active IP Right Cessation
-
2006
- 2006-10-25 HK HK06111785.0A patent/HK1091127A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1648520B1 (de) | 2010-05-05 |
| CN1852741A (zh) | 2006-10-25 |
| CA2532630A1 (en) | 2005-01-27 |
| AU2004257367A1 (en) | 2005-01-27 |
| WO2005007199A1 (en) | 2005-01-27 |
| US20050036994A1 (en) | 2005-02-17 |
| DE602004027048D1 (de) | 2010-06-17 |
| JP2007528862A (ja) | 2007-10-18 |
| EP1648520A1 (de) | 2006-04-26 |
| HK1091127A1 (en) | 2007-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1091127A1 (en) | Compounds and methods for downregulating the effects of tgf-beta | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
| MXPA05013977A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| ATE439868T1 (de) | Targetingmittel für molekulare bilderzeugung | |
| CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
| CY1116992T1 (el) | Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17 | |
| DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| EA200501771A1 (ru) | Лиганды каннабиноидных рецепторов и их применения | |
| HUP0301835A2 (hu) | Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva | |
| EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| BRPI0512500A (pt) | tratamento ou condições envolvendo desmielinação | |
| NO20062300L (no) | Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser | |
| BRPI0418384A (pt) | composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes | |
| DE60228484D1 (de) | Cytotoxische mittel | |
| ECSP045397A (es) | 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS | |
| CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
| EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
| ATE399532T1 (de) | Medizinische seife | |
| CY1110043T1 (el) | 2-αμινοβενζουλ παραγωγα | |
| ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa | |
| ATE346040T1 (de) | Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit | |
| TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
| MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |